TY - JOUR
T1 - Recurrence characteristics after focal salvage HDR brachytherapy in prostate cancer
AU - Rasing, Marnix J.A.
AU - Peters, Max
AU - van Son, Marieke
AU - Moerland, Marinus A.
AU - Eppinga, Wietse
AU - van de Pol, Sandrine M.G.
AU - Noteboom, Juus
AU - Lagendijk, Jan
AU - van der Voort van Zyp, Jochem R.N.
N1 - Funding Information:
We received external funding by the KWF Dutch Cancer Society (Grant No 10932) in support of our research on focal HDR brachytherapy for prostate cancer, which covered the current study.
Publisher Copyright:
© 2023 The Author(s)
PY - 2023/3
Y1 - 2023/3
N2 - Background and purpose: Radiorecurrent prostate cancer is often confined to the prostate, predominantly near the index lesion. The purpose of this study was to look at recurrence characteristics in patients treated with focal salvage high dose-rate (HDR) brachytherapy. Materials and methods: Patients treated with MRI-guided HDR brachytherapy, with a single fraction of 19 Gy from July 2013 to October 2021 as focal salvage treatment, were prospectively included in the current study. Imaging data were collected regarding the occurrence of local, regional and distant recurrences, including location of local recurrences (LR) in relation to the HDR radiotherapy field. Results: One hundred seventy-five patients were included after focal salvage HDR brachytherapy (median follow-up 36 months (IQR 23–50)). Three-years biochemical recurrence-free survival, LR-free survival, in-field LR-free survival, out-of-field LR-free survival, any-recurrence-free survival and ADT-free survival were 43% (95%CI 34%–52%), 51% (41%–61%), 70% (61%–80%), 92% (88%–97%), 42% (32%–52%) and 86% (80%–92%), respectively. Larger GTV-size and shorter PSA doubling time were associated with in-field LR in multivariable analysis. Conclusion: After focal salvage HDR brachytherapy with a dose of 1x19 Gy for local prostate cancer recurrence, subsequent recurrences are mostly local and in-field.
AB - Background and purpose: Radiorecurrent prostate cancer is often confined to the prostate, predominantly near the index lesion. The purpose of this study was to look at recurrence characteristics in patients treated with focal salvage high dose-rate (HDR) brachytherapy. Materials and methods: Patients treated with MRI-guided HDR brachytherapy, with a single fraction of 19 Gy from July 2013 to October 2021 as focal salvage treatment, were prospectively included in the current study. Imaging data were collected regarding the occurrence of local, regional and distant recurrences, including location of local recurrences (LR) in relation to the HDR radiotherapy field. Results: One hundred seventy-five patients were included after focal salvage HDR brachytherapy (median follow-up 36 months (IQR 23–50)). Three-years biochemical recurrence-free survival, LR-free survival, in-field LR-free survival, out-of-field LR-free survival, any-recurrence-free survival and ADT-free survival were 43% (95%CI 34%–52%), 51% (41%–61%), 70% (61%–80%), 92% (88%–97%), 42% (32%–52%) and 86% (80%–92%), respectively. Larger GTV-size and shorter PSA doubling time were associated with in-field LR in multivariable analysis. Conclusion: After focal salvage HDR brachytherapy with a dose of 1x19 Gy for local prostate cancer recurrence, subsequent recurrences are mostly local and in-field.
KW - Brachytherapy
KW - Focal salvage
KW - HDR
KW - Prostate cancer
KW - Recurrence
UR - http://www.scopus.com/inward/record.url?scp=85147205807&partnerID=8YFLogxK
U2 - 10.1016/j.radonc.2023.109495
DO - 10.1016/j.radonc.2023.109495
M3 - Article
C2 - 36708924
AN - SCOPUS:85147205807
SN - 0167-8140
VL - 180
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
M1 - 109495
ER -